Compare IQIYI Inc - ADR (IQ) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IQIYI Inc - ADR vs Recursion Pharmaceuticals Inc — how do they compare? IQIYI Inc - ADR trades at $1.22 (market cap $1.20B), while Recursion Pharmaceuticals Inc trades at $2.93 (market cap $1.53B). The key difference: Recursion Pharmaceuticals Inc is the larger of the two by market cap, and IQIYI Inc - ADR is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| IQ | RXRX | |
|---|---|---|
Market Cap | $1.20B | $1.53B |
Sector | Media | Health |
52-Week High | $2.79 | $6.79 |
52-Week Low | $0.96 | $2.84 |
Enterprise Value | $2.76B | $946.50M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IQ stock trades at $1.235, up 3.78% today, with a bullish technical signal and mixed fundamentals. Revenue declined to $27.29B in 2025 with a net loss of $206.31M, but valuation ratios like P/S of 0.3 and P/B of 0.6 appear low. Recent news highlights AI initiatives and leadership changes, while analyst consensus is split with 50% buy ratings.
The outlook is cautious due to profitability challenges and projected revenue decline in 2026, but low valuations and AI-driven content strategy offer potential upside. Key risks include competitive pressures in streaming and regulatory uncertainty in China.
RXRX trades at $2.89, down 1.87% on the day, reflecting a challenging fundamental backdrop with a net income margin of -851.51% and negative cash flow from operations. The technical picture is bearish, though the stock has beaten earnings estimates for the last three quarters. Recent news highlights its AI-driven drug discovery platform and significant institutional interest, including purchases by Cathie Wood's Ark Invest.
The outlook remains speculative; the high analyst price target of $7.83 suggests significant upside potential, but this is contingent on the company successfully commercializing its pipeline. Key risks include persistent cash burn, intense competition, and the inherent uncertainty of clinical-stage biotech development.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IQIYI Inc - ADR
iQIYI Inc is an online entertainment service provider in China. It is primarily engaged in providing a variety of services encompassing internet video, live broadcasting, online games, online literature, animations, e-commerce, and social media platform. The company produces original video content and distributes appealing professionally produced content, partner-generated content, and user-generated content. It also offers a diverse collection of internet video content that appeals to users from broad demographics. The company's revenue is generated from membership services and online advertising services. The company earns most of its revenue from China.
Read more on IQ →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
